REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
Status:
Terminated
Trial end date:
2020-06-02
Target enrollment:
Participant gender:
Summary
This study will attempt to confirm the hypothesis that Idelalisib may represent a new
therapeutic alternative for patients with ALL in a set of particularly complex scenarios:
relapsed, refractory to conventional treatments, and old age. For this reason, the primary
objective is the overall response rate [ORR, defined as complete response (CR) or CR with
partial hematologic recovery (CRh) and response duration (RD) in adult patients with relapsed
or refractory ALL, or in adult ALL patients who are not suitable for treatment with
conventional therapies.